home / stock / psttf / psttf quote
Last: | $0.145 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.145 |
High: | $0 |
Low: | $0 |
Volume: | 100,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.145 | $0 | $0.145 | $0 | $0 | 100,000 | 01-17-2023 |
$0.145 | $0 | $0.145 | $0 | $0 | 2,000 | 09-27-2022 |
$0.145 | $0.145 | $0.145 | $0.145 | $0.145 | 2,000 | 08-25-2022 |
$0.16 | $0.16 | $0.16 | $0.16 | $0.16 | 2,000 | 08-02-2022 |
$0.055 | $0.055 | $0.055 | $0.055 | $0.055 | 3,000 | 10-13-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-28-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-27-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-24-2020 |
$ | $N/A | $0.045 | $N/A | $N/A | 0 | 01-23-2020 |
News, Short Squeeze, Breakout and More Instantly...
Prescient Therapeutics Ltd Company Name:
PSTTF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the results of its PTX-100 Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) in Californi...
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting. The team briefed an exp...
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL). The designation from the Office of Orphan Product...